Literatuur
- Uijen M. et al. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: a systematic review. Cancer Treatment Reviews. 2020; 89:102069
- Uijen M. et al. Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma. Oral Oncol 2022; 125:105703
- Boxtel W. van et al. Improving survival in salivary duct cancer with adjuvant androgen deprivation therapy. Oncotarget. 2019; 10(39):3833-3834
- Takahashi H. et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2019; 37(2):125-134
Commissie BOM adviezen
Ga naar de commissie BOM adviezen over hoofd-halstumor.
Richtlijnen
Ga naar de richtlijn Hoofd-halstumoren in de FMS richtlijnendatabase.